Alembic Pharmaceuticals receives USFDA final approval for Oseltamivir Phosphate oral suspension (6 mg/mL)

What Alembic announced

On 26 June 2026, Alembic Pharmaceuticals Limited informed the NSE and BSE that it had obtained final approval from the United States Food & Drug Administration (USFDA) for its Oseltamivir Phosphate oral suspension, 6 mg/mL. The announcement was made through a press release attached to a filing with the exchanges, and the company’s secretary, Manisha Saraf, signed the intimation. The approval pertains to an Abbreviated New Drug Application (ANDA) that the company had previously submitted.

"Alembic Pharmaceuticals Limited receives USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL."

The filing does not disclose any commercial launch dates, pricing, or immediate revenue expectations, but it confirms that the product now meets US regulatory standards for sale in the United States.

USFDA approval details

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Tamiflu Oral Suspension, 6 mg/mL marketed by Hoffmann‑La Roche. Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) indicated for two primary uses:

1. Treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older who have been symptomatic for no more than 48 hours.
2. Prophylaxis of influenza A and B in patients 1 year and older.

The approval adds to Alembic’s cumulative total of 243 USFDA ANDA approvals, of which 223 are final approvals and 20 are tentative approvals. This track record underscores the company’s long‑standing capability to navigate US regulatory pathways for generic medicines.

Market opportunity

According to IQVIA, the estimated US market size for Oseltamivir Phosphate oral suspension, 6 mg/mL, is US$27 million for the twelve‑month period ending March 2026. The market estimate reflects demand for both treatment and prophylaxis of seasonal influenza, a segment that experiences predictable seasonal spikes. While the filing does not provide a forecast of Alembic’s share of this market, the approval positions the company to compete directly with the branded product Tamiflu, potentially leveraging its cost‑competitive generic manufacturing capabilities.

Key facts at a glance

Why this matters for investors

The approval expands Alembic’s product portfolio in the influenza generic segment, a therapeutic area with recurring demand each year. By securing USFDA clearance, the company can export the product to the United States, a market that typically offers higher pricing power compared with many emerging markets. The addition of a product that is therapeutically equivalent to a well‑known branded drug may also enhance Alembic’s brand credibility among physicians and payors.

From a regulatory standpoint, the filing reinforces Alembian’s track record of successful US FDA submissions, which can be a positive signal for future generic pipelines. However, the announcement does not disclose any financial commitments, expected launch timelines, or projected sales, so investors should treat the information as a qualitative milestone rather than a quantified revenue driver at this stage.

Conclusion

Alembic Pharmaceuticals has achieved a significant regulatory milestone by obtaining USFDA final approval for its 6 mg/mL Oseltamivir Phosphate oral suspension. The product is positioned against a $27 million US market and adds to the company’s extensive portfolio of 243 USFDA ANDA approvals. While the filing confirms regulatory clearance, it does not provide details on commercial rollout or financial impact, leaving those aspects to be clarified in future disclosures.